Feasibility of combination therapy with quizartinib and chemotherapy has been shown in several phase II trials [17, 18] inducing a double-blinded, randomized phase III study of quizartinib with induction and consolidation chemotherapy and as maintenance in patients with newly diagnosed FLT3-ITD AML (ClincalTrials.gov identifier: NCT02668653) [19]. The gene discussed is FLT3; the disease is acute myeloid leukemia.